This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J.P. Morgan Healthcare Confab Live Blog: Day Two


SAN FRANCISCO (TheStreet) -- I'm alive! I survived Day One of the J.P. Morgan Healthcare Conference and a night of drinking. Happy to be back providing live coverage on Day Two, with featured presentations by Regeneron Pharma (REGN - Get Report), Vertex Pharma (VRTX - Get Report), Amgen (AMGN - Get Report) and Opko Health (OPK - Get Report).

Today's live blog will operate much like yesterday's. I will be posting news updates and analysis throughout the day, live from the presentation rooms and breakout (Q&A) sessions. You can also follow me on Twitter, my handle is @adamfeuerstein.

Your best bet is to check back into the live blog several times throughout the day. Feel free to ping me with questions and comments. I'll do my best to respond and keep the live blog as interactive as possible.

Here's my planned schedule for Tuesday, subject to change, of course. All times Eastern.

Regeneron 10:30 am
Alkermes (ALKS) 11 am
Vertex 11:30 am
Amgen 12:30 pm
Enanta Pharma (ENTA) 2 pm
Orexigen (OREX - Get Report) 2:30 pm
Ariad Pharma (ARIA) 6 pm
Opko 7:30 pm

More drinking and eating 8 pm to ???

-- Reported by Adam Feuerstein in San Francisco.  

Must Read: Vanda Pharma FDA Panel Live Blog

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $153.17 -0.70%
OREX $0.38 -6.70%
OPK $9.73 -0.21%
REGN $369.91 -2.10%
VRTX $85.55 1.80%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs